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Abstract
Aim: To estimate the occurrence of complications related to early-onset type 2 dia-
betes compared with type 1 diabetes.
Methods: All individuals registered in the Swedish Pediatric Quality Diabetes Regis-
ter and the Swedish National Diabetes Register with type 2 diabetes diagnosis at 10
to 25 years of age between 1996 and 2014 (n = 1413) were included. As controls,
individuals with type 1 diabetes were randomly selected from the same registers and
were matched for age, sex, and year-of-onset (n = 3748).
Results: Of the adolescents with type 2 diabetes in the pediatric register, 7.7% had
microalbuminuria and 24.6% had signs of retinopathy 5 years after diagnosis, whereas
the adolescents with type 1 diabetes 3.8% had microalbuminuria and 19.2% had reti-
nopathy. Among the young adults with type 2 diabetes from the adult diabetes regis-
ter 10 years after diagnosis 15.2% had microalbuminuria and 39.7% retinopathy,
whereas the young adults with type 1 diabetes 4.8% had microalbuminuria and 43.8%
retinopathy. After adjustment for established risk factors measured over time in the
whole combined cohort, individuals with type 2 diabetes had significantly higher risk
of microalbuminuria with a hazard ratio (HR) of 3.32 (95% confidence interval, CI
2.86-3.85, P < .001), and retinopathy with a HR of 1.17 (95% CI 1.06-1.30, P 0.04).
Conclusions: The prevalence of complications and comorbidities was higher among
those with type 2 diabetes compared with type 1 diabetes, although prevalent in both
groups. Early monitoring and more active treatment of type 2 diabetes in young indi-
viduals is required.
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1 | INTRODUCTION
The prevalence of type 2 diabetes among children and adolescents is
increasing in several parts of the world. In the United States, the over-
all incidence of type 2 diabetes in youth has increased from 9 to 12.5
cases per 100 000 youth per year from 2002-2003 to 2011-2012.1,2
Large international variations of prediabetes and type 2 diabetes are
apparent, with higher rates among certain ethnicities and populations,
and the lowest incidence rate and prevalence in European countries.
Austria have reported among the lowest incidence rates with 0.29 per
100 000 person-years,3 compared with the highest incidence rates
among Pima Indians in the United States with 330 per 100 000 per-
son-years.4 In Germany, the prevalence of type 2 diabetes in children
is low with a prevalence rate of 2.42 per 100.000 youth under
20 years of age, and has remained unchanged over the past decade.5,6
The differences in prevalence and incidence are caused by both popu-
lation characteristics and methodological differences,7 which make
comparisons between countries rather difficult. The prevalence of
early-onset type 2 diabetes in Sweden is not fully known, the overall
incidence rate of diabetes was estimated in Kronoberg region in the
south of Sweden between 1998 and 2001, and among children 0 to
19 years of age the incidence rate for type 2 diabetes was 3.1 per
100 000 person-years.8 Previous screening studies in Sweden have
found no cases of silent type 2 diabetes in healthy school children 11
to 13 years of age, nor in children with severe obesity treated at obe-
sity clinic.9,10 In contrast the prevalence of prediabetes is observed to
be rather high among obese children in Sweden, three times higher
than in a cohort of obese children in Germany.10,11 Impaired fasting
glucose among obese Swedish children has an association with the
development of type 2 diabetes in young adulthood and there are also
indications of a rapid increase in type 2 diabetes in young adults.12
Individuals with early-onset type 2 diabetes have a worse risk fac-
tor profile at diagnosis, and the disease seems to be more progressive
and pathogenic the earlier the onset of type 2 diabetes.13-17 The pat-
tern of complications is similar for both type 1 and type 2 diabetes,
both are associated with an increased risk of micro- and
macrovascular complications,13,17,18 although recent studies have
suggested that young adults with type 2 diabetes onset below
30 years of age have a higher metabolic risk compared with young
adults with type 1 diabetes in both Australia and United States.14,19
Given those findings, this study was designed to estimate the inci-
dence of reported cases of type 2 diabetes among adolescents and
young adults in Sweden and to evaluate the risk of developing complica-
tions related to early-onset type 2 diabetes, such as microalbuminuria
and retinopathy, among adolescents and young adults with type 2 dia-
betes, as compared to patients with type 1 diabetes.
2 | RESEARCH DESIGN AND METHOD
We used data from two National Diabetes Quality Registries; the
Swedish Pediatric Diabetes Quality Registry (SWEDIABKIDS) and the
Swedish National Diabetes Register (NDR) from 1996 until 2014.
2.1 | Data sources
2.1.1 | The Swedish Pediatric Quality Registry,
SWEDIABKIDS
The SWEDIABKIDS (SWE) database was established in 2000 as a
Swedish national clinical quality register that aims to support and
monitor diabetes care in children. Outpatient attendance data from all
Swedish pediatric diabetes centers are registered in SWE, and from
2007 all Swedish pediatric diabetes centers (n = 43) report to the reg-
ister and include data on almost all (approximately 99%) children and
adolescents with diabetes in Sweden.20 In Sweden, pediatric diabetes
centers treat all children aged 0 to 18 years with diabetes of all types
within their area. According to Swedish guidelines, which are based
on ISPAD guidelines, children with diabetes visit a pediatric diabetes
center at least four times annually and patient clinical data are
reported into the SWE by trained nurses or physician21,22 (http://
www.ndr.nu/SWE).
2.1.2 | The Swedish National Diabetes
Register, NDR
The Swedish National Diabetes Register (NDR) was initiated in 1996
as a nationwide clinical quality register for monitoring and supporting
diabetes care in Sweden, it includes patients with diabetes (both type
1 and 2) aged >18 years. As with SWE, more and more clinics have
over the years commenced participating in the NDR and in 2012 more
that 90% of all adult patients with diabetes were included.23,24 The
data is collected by trained nurses and physicians and include informa-
tion obtained in primary care and hospital outpatient clinics. Patient
data is either continuously reported approximately annually via elec-
tronic patient clinical records or registered directly into the NDR, and
it contains clinical data on about 90% of all adults with type 1 or 2 dia-
betes in Sweden (NDR year report 2019, https://www.ndr.nu).
Both SWE and the NDR are financially supported by the associa-
tion of Local Authorities and Regions, SALAR, which represents the
governmental, professional, and employer-related interests of Swe-
den´s municipalities, country councils, and regions and the data is
continuously validated.25,26 None of the registries collect data on eth-
nicity, socioeconomic status, or educational level. Each patient pro-
vides informed consent (verbal or written) before participation in the
registers. The study was designed by two of the authors (A.E.E., C.M.)
and ethical approval to conduct this study was approved by the
Regional Ethics Committee in Stockholm, Sweden.
2.1.3 | Study population
Adolescents and young adults aged 10 to 25 years with newly diag-
nosed type 2 diabetes between 1996 until 2014 were identified in
the SWEDIABKIDS and the NDR. At baseline, defined as the first
entry in the SWE or NDR, each patient with type 2 diabetes was
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matched for age, sex, and year-of-onset with approximately four indi-
viduals with type 1 diabetes who were randomly selected from the
SWE/NDR. Type 2 diabetes was defined by the reporting physician,
in Sweden the World Health Organization (WHO) diagnostic criteria is
used to diagnose diabetes,27 aided by determination of C-peptide,
autoantibodies, and fasting levels of insulin that is part of standard
care in Sweden.28 Eight patients changed diagnosis when referred
from the childhood register (SWE) to the register for adults (NDR) and
they were subsequently excluded due to risk of misclassification. A
subset of patients was not included in analysis of incidence but were
analyzed for outcome measures in the multivariable analysis, since
they were diagnosed with diabetes before SWE started in 2000
(n = 165). A flowchart depicting included and excluded participants is
shown in Figure 1.
Since the data is collected from two separate registers, the details
from the separate registers are further described below.
2.1.4 | Adolescents from SWE
Data on all patients diagnosed with type 2 diabetes with an age of 10
to 17.9 years at onset of diabetes, with at least one entry in SWE
between 1 January 2000 until 31 December 2014, were obtained
from the register and included in the study. One hundred fifty-three
F IGURE 1 Flow chart of analyses of adolescents and young adults with diabetes registered in SWEDIABKIDS and the National Diabetes
Register
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patients with type 2 diabetes were reported during this time period,
and 735 age, sex, and diabetes duration-matched patients with type 1
diabetes were found and will, for simplicity, be referred to as adoles-
cents although a small number still are children. The adolescents with
type 2 diabetes from SWE and the age-matched patients with type 1
diabetes with available data at follow up at 5 years of follow up, were
analyzed for the outcomes.
2.1.5 | Young adults from NDR
Data on all patients diagnosed with type 2 diabetes aged 18 to
25 years at onset of diabetes, with at least one entry in NDR from 1
January 1996 until 31 December 2014 were included in the study.
About 1260 patients with type 2 diabetes were reported during this
time period, and 3013 matched patients with type 1 diabetes were
found and will all be referred to as young adults.
The young adults with type 2 diabetes from NDR and the age-
matched patients with type 1 diabetes with available data at follow up
at 10 years of follow up, were analyzed for the outcomes.
2.1.6 | Combined cohort
We constructed one cohort out of the two cohorts from SWE and
NDR. During the years 1996 to 2014, 1421 patients with type 2 dia-
betes with an age of 10 to 25 years at diabetes onset were reported
in the registers combined, and 3748 patients with type 1 diabetes
with a similar age of onset were identified. Since eight patients chan-
ged diagnose in transition from SWE to NDR, 1413 individuals with
type 2 diabetes were therefore analyzed in the main cohort. All
patients together from both registers had a median time to follow up
of 3.5 years (range 0-14 years, mean 4 years). Thus, we studied indi-
viduals who were enrolled in SWE and NDR in the same year they
were diagnosed with diabetes and we followed them for up to
14 years, but with varying time to follow up due to different year of
diabetes onset. Outcome measures for all with available data at follow
up were analyzed. Our final cohort consisted of 5161 individuals con-
tributing to 40 663 observations. From both registers we have col-
lected data on diabetes type, hemoglobin A1c (HbA1c), weight,
height, body mass index (BMI), age at onset, gender, diabetes dura-
tion, systolic and diastolic blood pressure, micro- and macro-albumin-
uria, results from retinal photograph, and type of treatment from all
registered outpatient visits from diagnosis until December 2014.
2.1.7 | HbA1c analysis and clinical parameters
All laboratory methods used in Sweden are standardized through the
External Quality Assurance in Laboratory Medicine in Sweden
(EQUALIS). The data on HbA1c was derived from capillary blood sam-
ples taken in connection with visits to the diabetes center or primary
care health care center and analyzed with Bayer/Siemens DCA-2000
or using local laboratory methods and presented as HbA1c Mono S
(%) method and converted to mmol/mol according to International
Federation of Clinical Chemistry (IFCC). The IFCC reference method
has been adopted in Sweden, and HbA1c levels will be presented as
IFCC (mmol/mol). Body mass index was calculated as weight in kilo-
grams (kg) divided by height in meters squared (m2). Overweight and
obesity was defined by international age- and gender-specific BMI
cut-offs, corresponding to adult BMI cut-offs of 25 and 30 kg/m2 at
18 years of age (ISO-BMI ≥25 and ISO-BMI ≥30).29 Systolic and dia-
stolic blood pressure were measured in mm Hg.
2.2 | Outcome measures
2.2.1 | Diabetic kidney disease
Microalbuminuria was defined as two positive results out of three
samples obtained within 1 year, measured with the use of urinary
albumin-to-creatinine ratio (ACR) ≥ 3.5 mg/mmol (in SI units which
corresponds to >30 mg/g) in a spot urine collection.30,31
2.2.2 | Diabetic retinopathy
Retinal status is assessed locally, that is, through fundus photography
performed by ophthalmologist and reported to the register. Retinopa-
thy was categorized as “yes” or “no,” stage of retinopathy was not
reported in the registry.
2.2.3 | Hypertension
Hypertension was defined as blood pressure levels 95th or greater
centile for age (<18 years), 140/90 mm Hg or higher (>18 years), or
documented use of antihypertensive therapy.32
2.3 | Statistical methods
Descriptive analyses calculated the mean ± SD for continuous vari-
ables and the number and percentage for categorical variables. When
analyzing differences between the two independent groups the Stu-
dent t test, the Mann-Whitney U (for non-parametric ordinal data),
and χ2 test (for differences in frequencies of complications) were
used. A sensitivity analysis, reciever operating characteristic (ROC)
curve, on the variables BMI, HbA1c, and blood pressure was made to
explore the associations with the outcomes; microalbuminuria and
retinopathy. The Kaplan-Meier analysis was used to calculate proba-
bility of complication-free survival, and differences between groups
were tested by the log-rank test. A Cox regression analysis was used
to assess the influence of different variables on the occurrence of
complications. To understand which factors were associated with the
risk of outcome, hazard ratios, and 95% CIs for the associations
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between diabetes type and each outcome were computed in sequen-
tially adjusted models. A base model was adjusted for age, gender, and
time from diagnosis was constructed and additional models explored
whether adjustment of the individual covariates reduced the strength
of associations: HbA1c, BMI, and systolic and diastolic blood pressure.
The significance of explanatory variables in the final multivariable
models are expressed as hazard ratios (HRs) and 95% CIs. All analyses
used two-sided P < .05 as statistically significant. Goodness of fit was
tested by log-likelihood. All analyses were performed with IBM SPSS
23.0 and 25.0 for MacOS (SPSS Inc, Chicago, Illinois).
3 | RESULTS
3.1 | Annual change in type 2 diabetes incidence
The frequencies of newly reported patients with type 2 diabetes are
shown in Figure 2, from the year 2000 when SWE was started as a
registry. Between 2000 and 2014, n = 1248 patients with type 2 dia-
betes were registered in SWE and NDR together, 675 females and
573 males. The number of patients registered increased significantly
every year, except for 2014, due to not fully covered registration
since data was retrieved from the registries in 2014. The adolescents
with type 2 diabetes had a median time of follow up of
6.7 ± 2.8 years, and the age-matched patients with type 1 diabetes
had 5.5 + 1.5 years. The young adults with type 2 diabetes and the
age-matched matched patients with type 1 diabetes from the NDR
with available data at follow up had a median time of follow up of
10.3 ± 1.1 years.
3.2 | Clinical characteristics at baseline and
follow up
Table 1 shows the baseline characteristics where both the adolescents
and young adults with type 2 diabetes had a higher average BMI with
a distribution of more overweight and obesity and a higher blood
pressure at diabetes onset compared with the adolescents with type 1
diabetes. The adolescents with type 2 diabetes had a lower HbA1c at
diagnosis compared with type 1 diabetes adolescents, although the
degree of missing data was higher among the individuals with type 1
diabetes. In contrast from the adolescents, the young adults had simi-
lar HbA1c levels at onset irrespective of diabetes type. Data on treat-
ment at baseline, that is, the first registration, show that the number
of individuals with type 2 diabetes who had a treatment of diet only
were higher among the young adults.
Table 2 shows the characteristics at follow up by diabetes type
and age group. The adolescents with type 2 diabetes were more over-
weight or obese, had lower HbA1c and fewer visits; 2.8 visits per year
compared with 4.1 visits per year for the adolescents with type 1 dia-
betes. At follow up, 24.6% of the adolescents with type 2 diabetes
had signs of retinopathy and 7.7% had microalbuminuria. Despite
higher HbA1c, the prevalence of complications was significantly lower
among the adolescents with type 1 diabetes, 19.2% had retinopathy
and 3.8% had microalbuminuria. The young adults with type 2 diabe-
tes were more overweight or obese, had hypertension and
microalbuminuria to a higher degree than the patients with type 1 dia-
betes. At follow up, 15.2% of the young adults with type 2 diabetes
had microalbuminuria whereas 4.8% of the patients with type 1 diabe-
tes had microalbuminuria. Neither HbA1c, number of visits nor
F IGURE 2 Frequencies of
reported cases of type 2 diabetes in
SWE and NDR, with an age of onset
of 10 to 25 years, between 2000 and
2014. Females and males are
displayed in separate histograms and
the age at onset of diabetes is
displayed in separate boxes. The
column proportions differ significantly
from each other, with an increasing
number of reported cases (P = .043)*
especially among females 14 to 17
and also 22 to 25 of age at onset of
diabetes (P = .034)*, differences in
frequencies are tested with Pearson
chi-square. **Fifty-one individuals in
NDR had a reported year of onset of
diabetes just before 18 years of age;
in NDR the year of onset is reported,
not the date of onset. Data withdrawn
from SWE/NDR in 2014, registration
is probably lacking in 2014 due to not
fully covered registration since data
was withdrawn from the registries
in 2014
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prevalence of retinopathy at follow up were significantly different
among type 2 adults as the matched individuals with type 1 diabetes.
3.3 | Association between outcomes and variables
Figure 3 displays in a ROC curve the association between the vari-
ables BMI, systolic, and diastolic blood pressure, and HbA1c and the
two separate outcomes microalbuminuria and retinopathy. BMI had
the strongest association with microalbuminuria in both types of dia-
betes, and HbA1c had the strongest association with retinopathy in
both types of diabetes.
3.4 | Association model for type 2 diabetes and
outcomes
Table 3 includes sequentially adjusted models for the associations of
diabetes type and each outcome to determine which risk factors con-
tributed to the higher risk among those with type 2 diabetes vs type
1. The base model was adjusted for age, sex, and diabetes duration
and showed significantly higher rates of microalbuminuria in type 2
diabetes, with further adjustment for HbA1c, BMI, and blood pressure
the association was slightly weaker but still significant. The base
model for the risk of retinopathy showed a small but significant
increased risk associated with type 2 diabetes. In an analysis stratified
for sex, the hazard for complications significantly increased in males
both for microalbuminuria and retinopathy, whereas the risk of reti-
nopathy was lower in females with type 2 diabetes compared with
type 1 diabetes.
3.5 | Association model for the two separate
diabetes types and outcomes
Table 4 shows the clinical and biochemical characteristics associated
with the development of complications separately for the different
diabetes types. Despite that the effect size is small, it reveals different
risk patterns for the two diabetes types and also gender differences.
The development of microalbuminuria in type 2 diabetes is associated
TABLE 1 Comparisons of clinical characteristics at first registration in adolescents and young adults with type 1 and 2 diabetes
Adolescents with diabetes diagnosis at 10
to 7.9 years of age (SWEDIABKIDS)
Young adults with diabetes diagnosis











735 153 3013 1095
Female, n (%) 352 (48.2) 79 (51) 0.360 1317 (43.7) 596 (54.4) <0.001
Age at diabetes onset (years) 14.8 ± 1.9 15.0 ± 1.9 0.139 20.9 ± 2.2 21.9 ± 2.2 0.631
BMI (kg/m2) 21.0 ± 3.9 34.1 ± 7.5 <0.001 23.9 ± 4.2 34.4 ± 7.7 <0.001
ISO BMI, n 444/97/18/176 9/21/97/26 <0.001 1550/532/191/740 94/159/593/249 <0.001
Nw/ow/obese/unknown (%) (60.4/13.2/2.4/23.9) (5.8/13.6/63/17) (51.4/17.7/6.3/24.6) (8.6/14.5/54.2/22.7)
HbA1c % (mmol/mol) 8.4 (68 ± 24) 6.9 (52 ± 14) <0.001 7.6 (60 ± 21) 7.5 (58 ± 21) 0.203
Missing, n (%) 265 (35.5) 35 (22.9) 315 (10.5) 130 (11.9)
Systolic blood pressure (mm Hg) 114.7 ± 11.5 122.7 ± 12.9 <0.001 118.1 ± 11.5 124.4 ± 13.5 <0.001
Diastolic blood pressure (mm
Hg)
66.4 ± 8.9 74.1 ± 9.2 <0.001 71.2 ± 8.7 76.1 ± 9.9 <0.001
Missing, n (%) 566 (77) 91 (59.5) 543 (18.0) 195 (17.8)
Treatment at onset, n (%)
Diet only - 11 (7.2) - 316 (28.9)
Oral medication only - 59 (38.6) 34 (1.1) 457 (41.7)
Insulin only 480 (65.3) 27 (17.6) 2658 (88.2) 145 (13.2)
Insulin and oral medication - 18 (11.8) 41 (1.4) 137 (12.5)
GLP-1 and/or combined
treatment
Missing, n (%) - - 1 (0.1) 5 (0.4)
255 (34.7) 38 (24.8) 102 (3.4) 36 (3.3)
Note: Values are displayed as mean ± SD in continuous variables and as frequencies (%) in categorical variables. P-values are derived from t test, ANOVA
or Mann-W U test for continuous variables and χ2 for categorical variables.
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HbA1c, hemoglobin A1c. ISO-BMI as levels
of obesity according to Cole. GLP-1, Glucagon-like peptide 1 agonist.
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with; male sex, BMI, systolic blood pressure and a significant but small
association with HbA1c levels. Development of retinopathy in type 2
diabetes was associated with male sex, higher levels of HbA1c and
higher systolic and diastolic blood pressure. In type 1 diabetes the
development of microalbuminuria was associated with female sex and
HbA1c levels. The development of retinopathy in type 1 diabetes was
associated with female sex, BMI, HbA1c, and higher diastolic blood
pressure.
3.6 | Kaplan-Meier curve of overall event-free
probability
The probability of microalbuminuria-free cumulative survival, that is,
developing signs of nephropathy related to diabetes duration, is
displayed in Figure 4A. Signs of diabetes related microalbuminuria
occurs earlier (P < .001) in diabetes type 2 compared with type 1 dia-
betes. The probability of retinopathy-free cumulative survival is dis-
played in Figure 4B. Retinopathy occurred earlier in type 2 diabetes
(P = .029) compared with type 1 diabetes, but there is no clinically rel-
evant difference in time to event.
4 | DISCUSSION
In this population-based study with information from two national
databases of diabetes in Sweden, SWE, and NDR, we found a succes-
sive increase in the number of reported cases of type 2 diabetes
among adolescents and young adults from 2000 to 2014. The young
patients were followed from diagnosis with repeated measures of risk
TABLE 2 Comparisons of clinical characteristics at follow up in two cohorts of adolescents and young adults with type 1 and 2 diabetes
Five years follow up of adolescents with diabetes
diagnosis at 10-17.9 years of age (SWEDIABKIDS)
10 years follow up in young adults with









Evaluated at follow up, n 499 130 883 297
Female, n (%) 241 (48.3) 68 (52.3) <0.001 407 (46.1) 177 (59.6) <0.001
Age (years) 21.3 ± 4.0 22.2 ± 3.7 0.02 32.2 ± 2.2 32.7 ± 2.0 0.465
Diabetes duration
(years)
5.5 ± 1.5 6.7 ± 2.8 0.036 10.3 ± 1.1 10.3 ± 1.1 0.911
No. of registrations/
year
4.1 ± 3.6 2.8 ± 3.3 <0.001 1.2 ± 1.2 1.3 ± 1.9 0.081
BMI (kg/m2) 23.9 ± 3.8 32.7 ± 7.5 <0.001 26.0 ± 4.4 32.1 ± 6.6 <0.001






















8/328 (2.4) 9/91 (9.9) <0.001 35/799 (4.4) 32/253 (12.6) <0.001
Retinopathy, n (%) 85/442 (19.2) 32/103 (24.6) 0.008 373/851 (43.8) 98/247 (39.7) 0.273
Microalbuminuria, n (%) 16/416 (3.8) 10/113 (7.7) 0.029 42/883 (4.8) 45/297 (15.2) <0.001
Treatment at follow up, n (%)
Diet only - 23 (17.7) 5 (0.6) 38 (12.8)
Oral medication only - 49 (37.7) 1 (0.1) 100 (33.7)
Insulin only 469 (94) 23 (17.9) 852 (96.5) 72 (24.2)
Insulin and oral
medication
2 (0.4) 22 (16.9) 16 (1.8) 80 (26.9)
GLP-1 and/or combined
treatment
- 9 (6.9) 1 (0.1) 3 (0.8)
Missing, n (%) 28 (5.6) 4 (3.1) 8 (0.9) 4 (1.3)
Note: Values are displayed as mean ± SD in continuous variables and as frequencies (%) in categorical variables. p-values are derived from t test, ANOVA or
Mann-W U test for continuous variables and χ2 for categorical variables.
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HbA1c, hemoglobin A1c. ISO-BMI as levels
of obesity according to Cole. GLP-1, Glucagon-like peptide 1 agonist.
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factors and complications over time during 5 to 10 years, and 15% of
individuals with type 2 diabetes had microalbuminuria and almost
40% developed retinopathy. The patients with type 2 diabetes
developed microalbuminuria earlier and also more frequently com-
pared with the age-, sex-, and years-of-onset–matched patients with
type 1 diabetes. Similar patterns have previously been demonstrated
(A) (B)
F IGURE 3 ROC curves for the association between variables and outcomes microalbuminuria and retinopathy in both type 1 and 2 diabetes

















HR (95% CI) 3.99 (3.49-4.36) 3.29 (2.80-3.85) 3.87 (3.45-4.34) 3.35 (2.91-3.86) 3.32 (2.86–3.85)
P-value <0.001 <0.001 <0.001 <0.001 <0.001
Retinopathy 2428/14739
HR (95% CI) 1.24 (1.14-1.35) 1.11 (1.00-1.23) 1.27 (1.17-1.39) 1.16 (1.04-1.28) 1.17 (1.06-1.30)
P-value <0.001 0.045 <0.001 0.006 0.04
Malesa
Microalbuminuria 460/8941
HR (95% CI) 5.49 (4.68-6.24) 4.99 (4.10-6.07) 5.26 (4.67-6.20) 4.90 (4.01-5.98) 4.92 (3.99-6.07)
P-value <0.001 <0.001 <0.001 <0.001 <0.001
Retinopathy 1236/7863
HR (95% CI) 1.59 (1.42-1.78) 1.64 (1.43-1.88) 1.51 (1.34-1.70) 1.63 (1.41-1.87) 1.64 (1.42-1.89)
P-value <0.001 <0.001 <0.001 <0.001 <0.001
Femalesa
Microalbuminuria 516/7800
HR (95% CI) 2.89 (2.48-3.37) 2.24 (1.84-2.72) 2.38 (1.95-2.91) 2.47 (1.97-3.09) 2.36 (1.91-2.91)
P-value <0.001 <0.001 <0.001 <0.001 <0.001
Retinopathy 1158/6752
HR (95% CI) 0.97 (0.83-1.1) 0.73 (0.62-0.85) 1.06 (0.94-1.21) 0.87 (0.67-0.81) 0.80 (0.68-0.95)
P-value 0.676 <0.001 0.323 0.002 0.008
Note: Base model adjusted for age, sex and diabetes duration. Goodness of fit was tested with quasi likelihood under independence criterion, and a P-value
of <.05 for the model indicates good fit.
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HR, hazard ratio.
aSex was not included in models for the separate sexes.
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in other cultural settings as United States and Australia,13,14,16,19,33
and we can now confirm the same situation in Sweden. In the present
study, the adolescents with type 2 diabetes were more frequently
obese compared with the young adults and showed more signs of
comorbidity. Despite lower HbA1c levels among the youngest
patients with type 2 diabetes at follow up compared with type 1 dia-
betes, the presence of microalbuminuria was higher among the
adolescents and also young adults with type 2 diabetes. These find-
ings, that are consistent with a report from a small number of type 2
diabetes patients from Australia,16 indicates that other factors than
HbA1c levels are of importance for the risk of developing complica-
tions among young individuals with type 2 diabetes. We also found a
small but significant difference in prevalence of retinopathy between
type 1 and 2 diabetes, which is in accordance with some,14 but not all
TABLE 4 Cox proportional hazard analysis of clinical and biochemical characteristics that predict development of complications in the
different diabetes types
Type 1 diabetes Type 2 diabetes
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Microalbuminuria
Sex (male vs female) 0.620 0.517-0.743 <0.001 1.276 1.06-1.54 0.012
Age at onset 0.894 0.865-0.925 <0.001 0.988 0.947-1.030 0.560
BMI (kg/m2) 1.001 0.982-1.020 0.898 1.025 1.012-1.039 <0.001
HbA1c (mmol/mol) 1.013 1.008-1.019 <0.001 1.005 1.001-1.010 0.028
Systolic blood pressure (mm Hg) 1.009 0.999-1.018 0.073 1.015 1.004-1.0017 <0.001
Diastolic blood pressure (mm Hg) 0.999 0.987-1.011 0.881 1.000 0.989-1.012 0.954
Retinopathy
Sex (male vs female) 0.819 0.745-0.901 <0.001 1.443 1.211-1.718 <0.001
Age at onset 0.980 0.960-0.999 0.041 1.005 0.968-1.043 0.800
BMI 1.013 1.003-1.022 0.012 1.004 0.991-1.017 0.570
HbA1c 1.016 1.013-1.019 <0.001 1.009 1.005-1.013 <0.001
Systolic blood pressure 1.004 0.999-1.009 0.147 1.008 1.001-1.016 0.034
Diastolic blood pressure 0.991 0.984-0.997 0.004 0.980 0.970-0.991 <0.001
Abbreviations: BMI, body mass index; CI, confidence interval; HbA1c, glycated hemoglobin A1c, HR, hazard ratio.
(A) (B)
F IGURE 4 A, Kaplan-Meier survival curve displaying the probability of microalbuminuria free survival in type 1 and 2 diabetes at means of
the covariates age, HbA1c, BMI, and blood pressure. Mean time to event in type 1 diabetes 123 months (with a 95% CI 122-124 months) and in
type 2 diabetes 108 months (with a 95% CI 107-110 months). Log rank test showed significant differences between type 1 and 2 diabetes with a
P-value of <0.001. B, Kaplan-Meier survival curve displaying the probability of retinopathy free survival in type 1 and 2 diabetes at means of
covariates age, HbA1c, BMI, and blood pressure, cumulative hazard of developing signs of diabetes retinopathy in type 1 and 2 diabetes. Mean
time to event in type 1 diabetes 113 months (with a 95% CI of 112-113 months) and in type 2 diabetes 108 months (with a 95% CI 109-
112 months). Log rank test showed significant differences between type 1 and 2 diabetes with a P-value of 0.029
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previous studies.34 Recently it has been suggested that type 2 diabe-
tes can be divided into clusters with different clinical pictures and
with different genetic patterns.35 Our results suggest that type 2 dia-
betes onset in an early age is more progressive and pathogenic dis-
ease than type 1 diabetes and also more aggressive than type 2
diabetes later in life which is in accordance with previous studies.15,36
It is unclear to which extent children with type 2 diabetes develop a
more aggressive type 2 diabetes due to their age or if young individ-
uals primarily are to be found in a genetic cluster with a more severe
type of diabetes. The multivariable analyses showed that in addition
to the type 2 diabetes diagnosis; BMI, HbA1c, and systolic blood pres-
sure were associated with the development of microalbuminuria but
most probably other factors not measured in this study also contrib-
ute. There was a markedly higher prevalence of both
microalbuminuria and retinopathy in males compared with females
with type 2 diabetes, despite same degree of obesity, this is in accor-
dance with a few earlier studies that suggests that men are more at
risk for microvascular complications compared with women.37-39 It is
well known that intensive treatment and frequent follow ups delays
the onset of long-term complications in both type 1 and 2 diabetes.40-
42 The fundamental treatment of type 2 diabetes is diet and physical
exercise, and to achieve effective weight treatment, several studies
have shown that early and intensive lifestyle treatment with frequent
contact and support from the health care providers is required.43-45 In
the present study, adolescents with type 2 diabetes had fewer visits
compared with the patients with type 1 diabetes, and we can also sus-
pect that some are lost to follow up. The majority of the patients
required pharmacological therapies, and this reflects the challenge for
medical care to encourage and maintain changes of lifestyle.
This study has several strengths. The study population was drawn
from two population-based quality registries of diabetes in Sweden
and has clinical characteristics similar to those of the overall popula-
tion from which it draws. The risk factors were measured longitudi-
nally, with repeated measurements over time, during a long time in
real-life diabetes management. However, this study has some limita-
tions. First, the classification of diabetes type in the registers is based
by the physician's opinion and experience, and although routine
check-up at diabetes diagnosis in Sweden includes testing of autoanti-
bodies and C-peptide according to ISPAD guidelines,28 we cannot cer-
tify that the diagnosis of diabetes type is correct. In NDR, individuals
with MODY (Maturity Onset of Diabetes in the Young) were at the
time of the study included in the type 2 diabetes cohort. Although a
very small group of patients, 1% to 2% of the diabetes population,46
this might affect the results regarding complications due to diabetes
as the most common variant (the glucokinase mutation) is not associ-
ated with complications.47-49 Third, the shorter time from diagnosis to
signs of microalbuminuria in the individuals with type 2 diabetes com-
pared with type 1 diabetes in the present study might be due to the
unclear duration of diabetes type 2. However, we have not found any
evidence of silent type 2 diabetes in Swedish children, neither at
screening for type 2 diabetes in school children,9 nor screening among
severely obese adolescents found any individuals with silent type 2
diabetes9,20,50,51 which contradicts a long preclinical course in early-
onset type 2 diabetes. Fourth, the patients, that is, the adolescents
and the young adults are from two separate registers and differ in
numbers of controls and female/male ratio. The withdrawal of data
from the registers revealed an unexpectedly high number of cases of
type 2 diabetes in the adult cohort in relation to the matched individ-
uals with type 1 diabetes. It was therefore not possible to match
according to study plan. Also, the time between visits were more vari-
able among the adolescents with type 2 diabetes, and fewer com-
pared with the controls with type 1 diabetes. This explains the
differences in numbers of females and males, and also numbers of
controls between the adolescents and young adults. Furthermore, as
presented in the Section 2 the registers have developed over time
and it is possible that some patients were not registered initially which
might affect the prevalence data. Patients who were diagnosed with
diabetes and registered in SWE or NDR from 1996 until 2014 were
included and subsequently followed over time retrospectively, thus
long-term data was limited for some patients. However, the marked
increased prevalence of complications was mainly observed for type 2
diabetes and not for type 1 and we have no reason to believe that
there is a registration bias between the two types of diabetes.
Another limitation is that there is missing data, especially concerning
microalbuminuria, but there was no significant difference in missing
data between the two diabetes types that can explain the differences.
We did not have any data on whether the degree of physical activity
or type of treatment could affect the differences between type 1 and
2 diabetes, nor did we have data on the ethnic background or educa-
tional level, since this type of information is not allowed in the regis-
ters, so we could not analyze whether the ethnic background differed
between type 1 and 2 diabetes.
In conclusion, in this longitudinal study of adolescents and young
adults with type 2 diabetes a high prevalence of diabetes-related com-
plications was found. Compared with type 1 diabetes and despite
lower HbA1c levels, the prevalence of microalbuminuria and hyper-
tension, 5 to 10 years after diagnosis was much higher. Together with
previous long-term data,19 this clearly indicates that these patients
are at higher risk for cardiovascular events. It is therefore important
to intensify the behavioral support and the pharmacological treatment
of comorbidities.52,53 Other treatment strategies aimed to improve
both metabolic control, weight loss, and cardiovascular fitness, such
as bariatric surgery54 should also be considered to reduce the future
health hazard, which both society and individual patients will bene-
fit from.
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